Active Not Recruiting PHASE4 INTERVENTIONAL 1-arm NCT03055598

Ferric Citrate in ESRD Pilot Project

Effect of Auryxia on ESA Utilization in ESRD Patients With High Ferritin & Low Transferrin Saturation: A Pilot Project

Sponsor: Keryx Biopharmaceuticals

Conditions Chronic Kidney Diseases End Stage Renal Disease

Updated 9 times since 2017 Last updated: Apr 15, 2019 Started: May 11, 2017 Primary completion: Sep 30, 2019 Completion: Feb 29, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03055598, this PHASE4 trial focuses on Chronic Kidney Diseases and End Stage Renal Disease and remains ongoing. Sponsored by Keryx Biopharmaceuticals, it has been updated 9 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Active Not Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE4
Jan 2021 — Jul 2024 [monthly]

Active Not Recruiting PHASE4
May 2019 — Jan 2021 [monthly]

Active Not Recruiting PHASE4

Status: Recruiting → Active Not Recruiting
Apr 2019 — May 2019 [monthly]

Recruiting PHASE4

▶ Show 4 earlier versions

Oct 2018 — Apr 2019 [monthly]

Recruiting PHASE4
Jun 2018 — Oct 2018 [monthly]

Recruiting PHASE4
Jun 2017 — Jun 2018 [monthly]

Recruiting PHASE4
Feb 2017 — Jun 2017 [monthly]

Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Keryx Biopharmaceuticals
Sreedhar Mandayam

Data source: Baylor College of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States